<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886689</url>
  </required_header>
  <id_info>
    <org_study_id>PCv1.6-12-11-05</org_study_id>
    <nct_id>NCT02886689</nct_id>
  </id_info>
  <brief_title>C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France</brief_title>
  <official_title>C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      C.O.R.P.U.S. is the first French observatory of care practices in active inflammatory&#xD;
      rheumatism of children and adults: rheumatoid arthritis, spondylarthropathy, and idiopathic&#xD;
      juvenile arthritis, established under the auspices of national health authorities.&#xD;
&#xD;
      Its goal is to document safety, effectiveness in routine practice of various therapy,&#xD;
      including biotherapy, of prescription or non-prescription over 5 years.&#xD;
&#xD;
      A cohort will be constituted including any new case of active disease (DAS 28 &gt; 3,2, BASDAI &gt;&#xD;
      4, failure of methotrexate), without previous prescription of biotherapy. Therefore, it will&#xD;
      be possible to have patients non exposed to biotherapy (non indication, refusal,&#xD;
      contraindication) compared to patients exposed to biotherapy, and to monitor adverse events&#xD;
      occurrence as well as effectiveness in routine practice over time, according to prescription,&#xD;
      maintenance or switch of various therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational:&#xD;
&#xD;
      Biotherapies, including anti-TNF alpha have demonstrated effectiveness by several randomized&#xD;
      clinical trials. The long-term use in clinical practice raise several questions regarding&#xD;
      their safety, the risk-benefit ratio, and the actual advantage of such treatment in real life&#xD;
      routine practice. Moreover such practice may considerably change, as far as increasing number&#xD;
      of therapies are made available on the market.&#xD;
&#xD;
      On request form national health authorities in France, this phase 4 study will help monitor&#xD;
      the changing strategies of prescription, the effectiveness and safety of these drugs.&#xD;
&#xD;
      Objectives :&#xD;
&#xD;
        1. to determine the impact of biotherapy prescription in 3 category of diseases assessed on&#xD;
           articular, functional and quality of life outcomes, as well as other drug consumption,&#xD;
           and to monitor adverse events&#xD;
&#xD;
        2. to determine the place of biotherapy in the sequence of treatments of patients&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      an open cohort study to include patients over 3 years continuously, and to last at least 5&#xD;
      years form study start, with annual prospective follow-up. C.O.R.P.U.S. will be the first&#xD;
      French observatory of prescription (or non-prescription) practices of biotherapy in first or&#xD;
      switch treatment.&#xD;
&#xD;
      Sample:&#xD;
&#xD;
      Patients will be recruited by French network of private rheumatologist, and 40 university&#xD;
      hospital rheumatology ward.&#xD;
&#xD;
      Data collected:&#xD;
&#xD;
      Socio-demographic, clinical parameters, function and quality of life know to have prognostic&#xD;
      value&#xD;
&#xD;
        -  Exposed patients will be those receiving any biotherapy&#xD;
&#xD;
        -  Non-exposed patients will be those not receiving biotherapy : non indication, refusal,&#xD;
           contraindication.&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      radiographic joint lesions, function, adverse events, maintenance rate, drug consumption.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      a sample of 1200 RA, 350 SPA and 300 IJA will be recruited every year for the first 3 years.&#xD;
&#xD;
      Adverse events:&#xD;
&#xD;
      Any adverse events will be reported to the national centre for pharmacovigilance.&#xD;
&#xD;
      IRB:&#xD;
&#xD;
      this protocol has been accepted by the CCTIRS and the CNIL.&#xD;
&#xD;
      Study monitoring:&#xD;
&#xD;
      A scientific committee has been constituted and is in charge of respect of any aspects of the&#xD;
      protocol, particularly regarding safety A steering committee has been constituted and&#xD;
      includes any drug company representative marketing such therapy, as well as representative of&#xD;
      Inserm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>first year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5400</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Spondylitis, Ankylosing</condition>
  <condition>Arthritis, Psoriatic</condition>
  <condition>Arthitis, Juvenile Idiopathic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients will be those receiving any biotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>patients will be those not receiving biotherapy : non indication, refusal, contraindication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF-alpha antagonist and other biotherapy</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering rheumatoid arthritis, spondyloarthropathy or idiopathic juvenile&#xD;
        arthritis, recruited with rheumatologist in public and private practice&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis by rheumatologist of rheumatoid arthritis&#xD;
&#xD;
          -  DAS score &gt; 3.2,&#xD;
&#xD;
          -  any age of onset&#xD;
&#xD;
          -  hand and feet x-ray within the past 3 months&#xD;
&#xD;
          -  never received any biotherapy Diagnosis by rheumatologist of spondylarthropathy&#xD;
             (ankylosing spondylitis, psoriasic arthritis)&#xD;
&#xD;
          -  active disease&#xD;
&#xD;
          -  hand and feet (peripheral) or spine (axial) x-ray within the past 3 months Diagnosis&#xD;
             by rheumatologist of idiopathic juvenile arthritis&#xD;
&#xD;
          -  failure or intolerance to methotrexate&#xD;
&#xD;
          -  x-ray within the past 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  received previous biotherapy&#xD;
&#xD;
          -  other spondylarthropathy than ankylosing spondylitis, psoriasic arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Guillemin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Benichou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU, Rouen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Sasraux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de la Cavale Blanche, Brest, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loic Guillevin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cochin, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Sibilia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Hautepierre, Strasbourg, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Marie Prieur, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Necker, Paris , France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Wendling, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Minioz, Besan√ßon, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hospital, Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>GUILLEMIN Francis, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>open to partnership</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

